#USA #New York #Class Action #Gross Law Firm #Regeneron Pharmaceuticals

Shareholders of Regeneron Pharmaceuticals, Inc. Urged to Contact The Gross Law Firm

In a recent announcement, The Gross Law Firm has reached out to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to inform them of important legal rights pertaining to their investments. The call to action is particularly relevant for those who acquired shares during the specified class period, which runs from November 2, 2023, to October 30, 2024.

Understanding the Allegations

The underlying case revolves around serious accusations against Regeneron. The claims highlighted in the lawsuit suggest that the company allegedly issued misleading statements and failed to disclose critical information that could affect investors' decisions. Specifically, it has been alleged that Regeneron made payments to distributors for credit card processing fees under certain conditions that were not transparently communicated.

Key Allegations include:

1. Concealing Financial Practices: The company purportedly paid credit card fees to distributors with the intent to keep credit card prices for their primary product, Eylea, at a lower rate for consumers.
2. Price Manipulation: These actions, it is claimed, allowed Regeneron to boost its reported sales figures for Eylea artificially.
3. Regulatory Violations: By not classifying credit card fee payments as price concessions, the company allegedly overstated the Average Selling Price (ASP) reported to federal agencies, breaching the False Claims Act in the process.
4. Misleading Statements: The firm’s public portrayal of its business and operational prospects is asserted to have been questionable and lacked a reasonable basis given the alleged actions taken.

Important Deadline for Shareholders

For shareholders of Regeneron, it’s crucial to understand that there is a pending deadline of March 10, 2025, for registering to participate in this legal action. Prospective participants are strongly encouraged not to delay, as the timeframe for filing is limited.

Next Steps for Interested Parties

Shareholders who acquired shares of Regeneron during the specified period are invited to register their information through the appropriate channels. By doing so, they will gain access to a portfolio monitoring service, which will keep them informed of updates throughout the litigation process. Participation in the action does not incur any costs or obligations for the shareholders.

Why Choose The Gross Law Firm?

The Gross Law Firm has established itself as a reputable national class-action law firm dedicated to safeguarding the rights of investors. The firm's mission is to ensure that organizations engage in fair business practices and that they are held accountable for actions that may harm investors. Their commitment to pursuing recovery for investors who have sustained losses from deceptive or misleading corporate conduct is evident.

Contact Information

Shareholders seeking more information or wishing to register can reach out to The Gross Law Firm directly:
Location: 15 West 38th Street, 12th Floor, New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Participating in a class action can be a crucial step in reclaiming potential losses for investors who feel they've been misled. Regeneron shareholders are advised to act promptly given the approaching deadline and the potential implications of the ongoing lawsuit.